FDA Approval Activities for this Drug…

Avandamet (rosiglitazone maleate/metformin HCl) Tablets, SB Pharmco Puerto Rico, NDA 21-410/S1 8/25/03 8/28/03 8/28/03 Avandamet (rosiglitazone maleate/metformin HCl) Tablets, 1 mg/500 mg, 2 mg/500 mg, and 4 mg/500 mg, GlaxoSmithKline NDA 21-410 10/10/02 10/21/02 10/17/02 4/30/03 Avandia (rosiglitazone maleate) Tablets, 2, 4, and 8 mg, GlaxoSmithKline NDA 21-071/S008 12/3/02 12/9/02 Avandia (rosiglitazone maleate) Tablets, 2, 4, and 8 mg, SmithKline Beecham . NDA 21-071/S004 2/27/03 3/10/03 3/11/03 Avandia (rosiglitazone maleate) Tablets, 2, 4, and 8 mg, SmithKline Beecham . NDA 21-071/S001 4/4/00 4/4/00 11/20/01 11/20/01 Avandia Indications: Use Avandia in combination with a sulfonylurea in patients with type 2 diabetes mellitus when diet and exercise with either single agent does not achieve adequate glycemic control. Avandia (rosiglitazone) Tablets, 2, 4, and 8 mg, SmithKline Beecham . NDA 21-071 5/25/99 6/1/99 6/1/99 11/20/01 Avandia Indications: Used as an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes mellitus as monotherapy or in combination with metformin. METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE Tablet; 1GM;EQ 2MG BASE AVANDAMET SB PHARMCO 021410 METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE Tablet; 1GM;EQ 4MG BASE AVANDAMET SB PHARMCO 021410 METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE Tablet; 500MG;EQ 1MG BASE AVANDAMET SB PHARMCO 021410 METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE Tablet; 500MG;EQ 2MG BASE AVANDAMET SB PHARMCO 021410 METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE Tablet; 500MG;EQ 4MG BASE AVANDAMET SB PHARMCO 021071 ROSIGLITAZONE MALEATE Tablet; 2MG BASE AVANDIA SB PHARMCO | 021071 ROSIGLITAZONE MALEATE Tablet; 4MG BASE AVANDIA SB PHARMCO | 021071 ROSIGLITAZONE MALEATE Tablet; 8MG BASE AVANDIA SB PHARMCO | Avandamet, GlaxoSmithKline | Avandia, GlaxoSmithKline | Avandia Tablet, GlaxoSmithKline, Labeling Revision | Avandamet Tablet, GlaxoSmithKline, Labeling Revision | Avandia (rosiglitazone maleate) Tablets, GlaxoSmithKline, New or Modified Indication

For the latest approval information, please see the main page.